Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Eribulin in advanced breast cancer
ChiCTR2100048468Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin in breast cancer, sponsored by Shandong Cancer Hospital. Primary endpoints: Objective response rate, Progression-free survival and 4 more. Started Jun 2021; status: recruiting.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100048468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048468.